title: The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS G12D -driven non-small cell lung cancer
design: MEFs maintained in DMEM supplemented with 10 % FBS. MLE-12 cells maintained in DMEM/F12 supplemented in 2.5% Tetracycline-free FBS. MEFs did not receive treatment, MLE-12 cells either received 100 ng/mL doxcycline (in ethanol) or ethanol control. Ethanol diluted 1:10,000. SureSelect (Agilent; full-length RNA; paired-end) cDNA libraries were prepared.
library_name: G12D_MLE-12_24hr_rep_2